SGLT2 Inhibitors – The New HF Therapies on the Block, Radcliffe Cardiology

Now Playing
Part 1 | Session 1 of 1
Welcome & Introductions
Subodh Verma

Up Next

Part 2 | Session 1 A Brief History of SGLT2 Inhibitors
Subodh Verma

Part 3 | Session 1 What Have We Learned About SGLT2 Inhibitors? A Clinical Perspective
Nikolaus Marx

Part 4 | Session 1 How Might Future Trials Affect How I Treat My Patients?
Shelley Zieroth

Part 5 | Session 1 Panel discussion
Subodh Verma, Nikolaus Marx, Shelley Zieroth

Overview

In this Educational Symposium from the e-SPACE Heart Failure Global Web-Conference, Subodh Verma, Nikolaus Marx and Shelley Zieroth discuss SGLT2 inhibitors covering their history, a clinical perspective into what we have learned about them and how future trials might affect clinical practice.

These videos were funded by an unrestricted educational grant from Boehringer Ingelheim & Eli Lilly and Company.

Learning objectives

Raise Awareness of SGLT2 Inhibitors as Cardiovascular Therapies With Cardio–Renal Benefits
Highlight Appropriate Patients for Initiation of an SGLT2 Inhibitor and Share With Cardiologists the Well-Established Safety Profile and Clinical Considerations for SGLT2 Inhibitor Treatment
Inform Cardiologists of the Current Evidence and Ongoing Trials for SGLT2 Inhibitors in Patients With HF

Agenda

5 mins - Welcome & introduction - Subodh Verma
15 mins - A brief history of SGLT2 inhibitors - Subodh Verma
15 mins - What have we learned about SGLT2 inhibitors? A clinical perspective - Nikolaus Marx
15 mins - How might future trials affect how I might treat my patients? - Shelley Zieroth
10 mins - Faculty discussion (pre-recorded) - All Faculty
Close - Subodh Verma
Live Q&A and discussion - All Faculty

More from this programme

Part 1

Welcome & Introductions

1 session
Welcome & Introductions	Watch now

Part 2

A Brief History of SGLT2 Inhibitors

1 session
A Brief History of SGLT2 Inhibitors	Watch now

Part 3

What Have We Learned About SGLT2 Inhibitors? A Clinical Perspective

1 session
What Have We Learned About SGLT2 Inhibitors? A Clinical Perspective	Watch now

Part 4

How Might Future Trials Affect How I Treat My Patients?

1 session
How Might Future Trials Affect How I Treat My Patients?	Watch now

Part 5

Panel discussion

1 session
Panel discussion	Watch now

Faculty Biographies

Subodh Verma

Dr Subodh Verma is a cardiac surgeon-scientist at St Michael’s Hospital and Professor in the Departments of Surgery, and Pharmacology and Toxicity at the University of Toronto. He is also the current Canada Research Chair in Cardiovascular Surgery.

Dr Verma oversees a prolific basic, translational and clinical research program. He spearheads the CARDIOLINK clinical trials platform at St Michael’s Hospital and has leadership roles in seven ongoing global heart failure trials.

View full profile